Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Ne...
Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms
About this item
Full title
Author / Creator
Pellat, Anna , Dreyer, Chantal , Couffignal, Camille , Walter, Thomas , Lombard-Bohas, Catherine , Niccoli, Patricia , Seitz, Jean François , Hentic, Olivia , André, Thierry , Coriat, Romain , Faivre, Sandrine , Zappa, Magaly , Ruszniewski, Philippe , Pote, Nicolas , Couvelard, Anne and Raymond, Eric
Publisher
Basel, Switzerland: S. Karger AG
Journal title
Language
English
Formats
Publication information
Publisher
Basel, Switzerland: S. Karger AG
Subjects
More information
Scope and Contents
Contents
Background/Aims: Angiogenesis is extensively developed in well-differentiated pancreatic neuroendocrine tumours (PanNET) where sunitinib was shown to prolong progression-free survival, leading to nationwide approval. However, clinical experience in patients with grade 3 gastroenteropancreatic neuroendocrine neoplasms (GEPNEN-G3) remains limited. Th...
Alternative Titles
Full title
Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_crossref_primary_10_1159_000487237
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_crossref_primary_10_1159_000487237
Other Identifiers
ISSN
0028-3835
E-ISSN
1423-0194
DOI
10.1159/000487237
